Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib with Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
NCT02783625Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2016
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of duvelisib in T-cell lymphoma (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started May 2016; status: completed.
02
Drugs
duvelisib
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT02783625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02783625.